Ocular cytochrome P450s and transporters: roles in disease and endobiotic and xenobiotic disposition

Abstract Drug metabolism and transport processes in the liver, intestine and kidney that affect the pharmacokinetics and pharmacodynamics of therapeutic agents have been studied extensively. In contrast, comparatively little research has been conducted on these topics as they pertain to the eye. Recently, however, catalytic functions of ocular cytochrome P450 enzymes have gained increasing attention, in large part due to the roles of CYP1B1 and CYP4V2 variants in primary congenital glaucoma and Bietti’s corneoretinal crystalline dystrophy, respectively. In this review, we discuss challenges to ophthalmic drug delivery, including Phase I drug metabolism and transport in the eye, and the role of three specific P450s, CYP4B1, CYP1B1 and CYP4V2 in ocular inflammation and genetically determined ocular disease.

[1]  E. Han,et al.  Prostaglandin E2 induces CYP1B1 expression via ligand-independent activation of the ERalpha pathway in human breast cancer cells. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[2]  V. Ganapathy,et al.  Molecular evidence and functional expression of P-glycoprotein (MDR1) in human and rabbit cornea and corneal epithelial cell lines. , 2003, Investigative ophthalmology & visual science.

[3]  A. Mitra,et al.  Mitochondrial localization of P-glycoprotein and peptide transporters in corneal epithelial cells--novel strategies for intracellular drug targeting. , 2013, Experimental eye research.

[4]  R. W. Young.  THE RENEWAL OF PHOTORECEPTOR CELL OUTER SEGMENTS , 1967, The Journal of cell biology.

[5]  B. Tusi,et al.  Contributions of MYOC and CYP1B1 mutations to JOAG , 2008, Molecular vision.

[6]  A. Rettie,et al.  Expression and Characterization of CYP4V2 as a Fatty Acid ω-Hydroxylase , 2009, Drug Metabolism and Disposition.

[7]  Francis L Martin,et al.  CYP1B1 and hormone-induced cancer. , 2012, Cancer letters.

[8]  Sergey V Mikhalovsky,et al.  Polymeric hydrogels for novel contact lens-based ophthalmic drug delivery systems: a review. , 2008, Contact lens & anterior eye : the journal of the British Contact Lens Association.

[9]  F. Curriero,et al.  Expression of cytochromes P450 1A1 and 1B1 in human lung from smokers, non-smokers, and ex-smokers. , 2004, Toxicology and applied pharmacology.

[10]  P. Majumder,et al.  Globally, CYP1B1 mutations in primary congenital glaucoma are strongly structured by geographic and haplotype backgrounds. , 2006, Investigative ophthalmology & visual science.

[11]  S. Yamamoto,et al.  Oxidation and keto reduction of 12-hydroxy-5,8,10,14-eicosatetraenoic acids in bovine corneal epithelial microsomes. , 1994, Biochimica et biophysica acta.

[12]  F. Aoki,et al.  Comparative bioavailability of acyclovir from oral valacyclovir and acyclovir in patients treated for recurrent genital herpes simplex virus infection. , 2001, The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique.

[13]  J. Masferrer,et al.  Inhibition of renal, cardiac and corneal (Na(+)-K+)ATPase by 12(R)-hydroxyeicosatetraenoic acid. , 1990, Biochemical pharmacology.

[14]  Kati-Sisko Vellonen,et al.  Drug transport in corneal epithelium and blood-retina barrier: emerging role of transporters in ocular pharmacokinetics. , 2006, Advanced drug delivery reviews.

[15]  Charles N. Serhan,et al.  Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers , 2004, Lipids.

[16]  Chetan Rao,et al.  Molecular screening of the CYP4V2 gene in Bietti crystalline dystrophy that is associated with choroidal neovascularization , 2011, Molecular vision.

[17]  M. Kaiser-Kupfer,et al.  Bietti crystalline corneoretinal dystrophy is caused by mutations in the novel gene CYP4V2. , 2004, American journal of human genetics.

[18]  C. Serhan,et al.  Rescue and repair during photoreceptor cell renewal mediated by docosahexaenoic acid-derived neuroprotectin D1 , 2010, Journal of Lipid Research.

[19]  R. Esilae.  HISTOCHEMICAL AND ELECTROPHORETIC PROPERTIES OF CHOLINESTERASES AND NON-SPECIFIC ESTERASES IN THE RETINA OF SOME MAMMALS, INCLUDING MAN. , 1963, Acta ophthalmologica. Supplementum.

[20]  S. Yin,et al.  Contribution to first-pass metabolism of ethanol and inhibition by ethanol for retinol oxidation in human alcohol dehydrogenase family--implications for etiology of fetal alcohol syndrome and alcohol-related diseases. , 1998, European journal of biochemistry.

[21]  Kimio Takeuchi,et al.  Crystal deposits on the lens capsules in Bietti crystalline corneoretinal dystrophy associated with a mutation in the CYP4V2 gene , 2009, Acta ophthalmologica.

[22]  R. W. Young.  Visual cells and the concept of renewal. , 1976, Investigative ophthalmology & visual science.

[23]  J. Hejtmancik,et al.  Clinical and genetic features in Italian Bietti crystalline dystrophy patients , 2012, British Journal of Ophthalmology.

[24]  J. Falck,et al.  Transfection of Cytochrome P4504B1 into the Cornea Increases Angiogenic Activity of the Limbal Vessels , 2005, Journal of Pharmacology and Experimental Therapeutics.

[25]  D. Zeldin,et al.  EDHF function in the ductus arteriosus: evidence against involvement of epoxyeicosatrienoic acids and 12S-hydroxyeicosatetraenoic acid. , 2009, American journal of physiology. Heart and circulatory physiology.

[26]  C. Simons,et al.  Exome sequencing in developmental eye disease leads to identification of causal variants in GJA8, CRYGC, PAX6 and CYP1B1 , 2013, European Journal of Human Genetics.

[27]  J. Zenteno,et al.  Novel CYP4V2 Gene Mutation in a Mexican Patient with Bietti's Crystalline Corneoretinal Dystrophy , 2008, Current Eye Research.

[28]  W. Gordon,et al.  Visualization of [3H]docosahexaenoic acid trafficking through photoreceptors and retinal pigment epithelium by electron microscopic autoradiography. , 1993, Investigative ophthalmology & visual science.

[29]  M. Walter,et al.  Further support of the role of CYP1B1 in patients with Peters anomaly. , 2006, Molecular vision.

[30]  A. Mitra,et al.  Pharmacokinetics of Novel Dipeptide Ester Prodrugs of Acyclovir after Oral Administration: Intestinal Absorption and Liver Metabolism , 2004, Journal of Pharmacology and Experimental Therapeutics.

[31]  M. Ingelman-Sundberg,et al.  Mutations in CYP1B1 cause primary congenital glaucoma by reduction of either activity or abundance of the enzyme , 2008, Human mutation.

[32]  A. Bonazzi,et al.  Regulation of Cyclooxygenase-2 by Hypoxia and Peroxisome Proliferators in the Corneal Epithelium* , 2000, The Journal of Biological Chemistry.

[33]  J. Falck,et al.  Hypoxia stimulates the synthesis of cytochrome P450-derived inflammatory eicosanoids in rabbit corneal epithelium. , 1998, The Journal of pharmacology and experimental therapeutics.

[34]  J. Schenkman,et al.  Effect of two mutations of human CYP1B1, G61E and R469W, on stability and endogenous steroid substrate metabolism. , 2001, Pharmacogenetics.

[35]  K. Elbedour,et al.  Congenital Glaucoma: CYP1B1 Mutations in Israeli Bedouin Kindreds , 2010, Journal of glaucoma.

[36]  F. Guengerich,et al.  Human cytochrome P-450 enzymes. , 1992, Life sciences.

[37]  Yanping Song,et al.  A novel mutation in the CYP4V2 gene in a Chinese patient with Bietti’s crystalline dystrophy , 2013, International Ophthalmology.

[38]  Y. Fujii‐Kuriyama,et al.  Identification of a meander region proline residue critical for heme binding to cytochrome P450: implications for the catalytic function of human CYP4B1. , 1998, Biochemistry.

[39]  H. Yamazaki,et al.  Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. , 1996, Cancer research.

[40]  A. Mitra,et al.  Molecular evidence and functional expression of a novel drug efflux pump (ABCC2) in human corneal epithelium and rabbit cornea and its role in ocular drug efflux. , 2007, International journal of pharmaceutics.

[41]  M. Sarfarazi,et al.  Identification of three different truncating mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenital glaucoma (Buphthalmos) in families linked to the GLC3A locus on chromosome 2p21. , 1997, Human molecular genetics.

[42]  P. Woollard.  Stereochemical difference between 12-hydroxy-5,8,10,14-eicosatetraenoic acid in platelets and psoriatic lesions. , 1986, Biochemical and biophysical research communications.

[43]  V. H. Lee,et al.  Esterase distribution in the rabbit cornea and its implications in ocular drug bioavailability. , 1982, Biopharmaceutics & drug disposition.

[44]  C. Leporini,et al.  Anti-vascular endothelial growth factor drugs safety and efficacy in ophthalmic diseases , 2013, Journal of pharmacology & pharmacotherapeutics.

[45]  Dawn M. Toolan,et al.  The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey , 2013, Neuropharmacology.

[46]  Xueshan Xiao,et al.  Identification of CYP4V2 mutation in 21 families and overview of mutation spectrum in Bietti crystalline corneoretinal dystrophy. , 2011, Biochemical and biophysical research communications.

[47]  T. Dryja,et al.  Recessive mutations in the CYP4V2 gene in East Asian and Middle Eastern patients with Bietti crystalline corneoretinal dystrophy , 2005, Journal of Medical Genetics.

[48]  J W Shell,et al.  Ophthalmic drug delivery systems , 1984, Survey of ophthalmology.

[49]  Xiaochao Ma,et al.  METABOLISM OF MELATONIN BY HUMAN CYTOCHROMES P450 , 2005, Drug Metabolism and Disposition.

[50]  J. Hardwick.  Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases. , 2008, Biochemical pharmacology.

[51]  V. H. Lee.  Esterase activities in adult rabbit eyes. , 1983, Journal of pharmaceutical sciences.

[52]  I. Thompson,et al.  CYP1B1 variants are associated with prostate cancer in non-Hispanic and Hispanic Caucasians , 2008, Carcinogenesis.

[53]  M. Tamai,et al.  Screening for mutations in CYP4V2 gene in Japanese patients with Bietti's crystalline corneoretinal dystrophy. , 2005, American journal of ophthalmology.

[54]  A. Mitra,et al.  Ophthalmic Drug Delivery Systems , 2003 .

[55]  M. Schwartzman,et al.  Effect of metabolic inhibitors on arachidonic acid metabolism in the corneal epithelium: evidence for cytochrome P450-mediated reactions. , 1994, Journal of ocular pharmacology.

[56]  N. Abraham,et al.  A closed eye contact lens model of corneal inflammation. Part 2: Inhibition of cytochrome P450 arachidonic acid metabolism alleviates inflammatory sequelae. , 1995, Investigative ophthalmology & visual science.

[57]  M. Kaiser-Kupfer,et al.  Clinical biochemical and pathologic correlations in Bietti's crystalline dystrophy. , 1994, American journal of ophthalmology.

[58]  T. Nakazawa,et al.  Mutation spectrum of the CYP1B1 gene for congenital glaucoma in the Japanese population , 2010, Japanese Journal of Ophthalmology.

[59]  S. Heys,et al.  Profiling the expression of cytochrome P450 in breast cancer , 2010, Histopathology.

[60]  Eric F. Johnson,et al.  Human Cytochrome P450 Family 4 Enzymes: Function, Genetic Variation and Regulation , 2007, Drug metabolism reviews.

[61]  M. Kaiser-Kupfer,et al.  The metabolism of fatty acids in human Bietti crystalline dystrophy. , 2001, Investigative ophthalmology & visual science.

[62]  D. Sarraf,et al.  West African crystalline maculopathy. , 2003, Archives of ophthalmology.

[63]  L. Maltais,et al.  Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. , 2004, Pharmacogenetics.

[64]  R. W. Young,et al.  Shedding of discs from rod outer segments in the rhesus monkey. , 1971, Journal of ultrastructure research.

[65]  M. Schwartzman,et al.  Hypoxia-induced production of 12-hydroxyeicosanoids in the corneal epithelium: involvement of a cytochrome P-4504B1 isoform. , 1999, The Journal of pharmacology and experimental therapeutics.

[66]  J. Falck,et al.  Absolute configuration of the hydroxyeicosatetraenoic acids (HETEs) formed during catalytic oxygenation of arachidonic acid by microsomal cytochrome P-450. , 1986, Biochemical and biophysical research communications.

[67]  V. Yarov-Yarovoy,et al.  Finding homes for orphan cytochrome P450s: CYP4V2 and CYP4F22 in disease states. , 2011, Molecular interventions.

[68]  M. Laniado-Schwartzman,et al.  Promoter activity and regulation of the corneal CYP4B1 gene by hypoxia , 2003, Journal of cellular biochemistry.

[69]  A. Rettie,et al.  Finding Homes for Orphan Cytochrome P 450 s : CYP 4 V 2 and CYP 4 F 22 in Disease States , 2011 .

[70]  R. Welch.  Bietti's tapetoretinal degeneration with marginal corneal dystrophy crystalline retinopathy. , 1977, Transactions of the American Ophthalmological Society.

[71]  Y. Inoue,et al.  Clinical and Molecular Findings in Three Japanese Patients with Crystalline Retinopathy , 2006, Japanese Journal of Ophthalmology.

[72]  P. Humphries,et al.  The Blood-Retina Barrier , 2013 .

[73]  V. Vasiliou,et al.  Role of CYP1B1 in glaucoma. , 2008, Annual review of pharmacology and toxicology.

[74]  H. D. Liggitt,et al.  Generation and characterization of a Cyp4b1 null mouse and the role of CYP4B1 in the activation and toxicity of Ipomeanol. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.

[75]  P. Sergouniotis,et al.  Bietti crystalline retinopathy: report of retinal crystal deposition in male adolescent siblings. , 2012, Archives of ophthalmology.

[76]  M. Schwartzman,et al.  Inhibition of VEGF expression and corneal neovascularization by siRNA targeting cytochrome P450 4B1. , 2007, Prostaglandins & other lipid mediators.

[77]  T. Ishii,et al.  Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor. , 2001, Bioorganic & medicinal chemistry letters.

[78]  M. Tomi,et al.  Advances in the cell biology of transport via the inner blood-retinal barrier: establishment of cell lines and transport functions. , 2005, Biological & pharmaceutical bulletin.

[79]  T. Aung,et al.  Characterization of Bietti crystalline dystrophy patients with CYP4V2 mutations. , 2005, Investigative ophthalmology & visual science.

[80]  M. Sarfarazi,et al.  Assignment of a locus (GLC3A) for primary congenital glaucoma (Buphthalmos) to 2p21 and evidence for genetic heterogeneity. , 1995, Genomics.

[81]  S. Cai,et al.  Exome Sequencing Identifies Compound Heterozygous Mutations in CYP4V2 in a Pedigree with Retinitis Pigmentosa , 2012, PloS one.

[82]  M. Tachikawa,et al.  Inner Blood-Retinal Barrier Transporters: Role of Retinal Drug Delivery , 2009, Pharmaceutical Research.

[83]  R. Murphy,et al.  Metabolism of 12(R)-hydroxy-5,8,10,14-eicosatetraenoic acid (12(R)-HETE) in corneal tissues: formation of novel metabolites. , 1991, Archives of biochemistry and biophysics.

[84]  Ching-Chyuan Su,et al.  Mutations in the CYP1B1 gene may contribute to juvenile-onset open-angle glaucoma , 2012, Eye.

[85]  L. Wilson,et al.  RALDH-independent generation of retinoic acid during vertebrate embryogenesis by CYP1B1 , 2007, Development.

[86]  V. Ganapathy,et al.  Identification of a Na+-dependent cationic and neutral amino acid transporter, B(0,+), in human and rabbit cornea. , 2004, Molecular pharmaceutics.

[87]  J. Schenkman,et al.  Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[88]  J. Dilley,et al.  Incidence and Prevalence of Herpes Simplex Virus Type 2 Infection in Persons Seeking Repeat HIV Counseling and Testing , 2003, Sexually transmitted diseases.

[89]  A. Rettie,et al.  CYP4V2 in Bietti's Crystalline Dystrophy: Ocular Localization, Metabolism of ω-3-Polyunsaturated Fatty Acids, and Functional Deficit of the p.H331P Variant , 2012, Molecular Pharmacology.

[90]  W. Pryor.  Cytochrome P450: Structure, mechanism, and biochemistry , 1996 .

[91]  D. Nebert,et al.  Genetic differences in drug metabolism associated with ocular toxicity. , 1982, Environmental health perspectives.

[92]  A. Mitra,et al.  Ocular penetration of acyclovir and its peptide prodrugs valacyclovir and val-valacyclovir following systemic administration in rabbits: An evaluation using ocular microdialysis and LC-MS , 2002, Current eye research.

[93]  D. Morck,et al.  Drug delivery to the posterior segment of the eye through hydrogel contact lenses , 2011, Clinical & experimental optometry.

[94]  R. Schoenwald,et al.  Corneal penetration behavior of beta-blocking agents II: Assessment of barrier contributions. , 1983, Journal of pharmaceutical sciences.

[95]  Takaaki Hayashi,et al.  CYP4V2 Mutations in Two Japanese Patients with Bietti’s Crystalline Dystrophy , 2005, Ophthalmic Research.

[96]  Peng Chen,et al.  Expression of Efflux Transporters in Human Ocular Tissues , 2013, Drug Metabolism and Disposition.

[97]  P. Humphries,et al.  The blood-retina barrier: tight junctions and barrier modulation. , 2012, Advances in experimental medicine and biology.

[98]  R. Klein,et al.  Causes and prevalence of visual impairment among adults in the United States. , 2004, Archives of ophthalmology.

[99]  N. Miyata,et al.  Cytochrome P450 4A isoform inhibitory profile of N-hydroxy-N'-(4-butyl-2-methylphenyl)-formamidine (HET0016), a selective inhibitor of 20-HETE synthesis. , 2005, Biological & pharmaceutical bulletin.

[100]  F. Testa,et al.  An Atypical Form of Bietti Crystalline Dystrophy , 2011, Ophthalmic genetics.

[101]  A. Mitra,et al.  Ocular pharmacokinetics of acyclovir amino acid ester prodrugs in the anterior chamber: evaluation of their utility in treating ocular HSV infections. , 2008, International journal of pharmaceutics.

[102]  A. Mitra,et al.  Identification and functional characterization of a Na+-independent large neutral amino acid transporter, LAT1, in human and rabbit cornea. , 2003, Investigative ophthalmology & visual science.

[103]  Y. Buys,et al.  Digenic inheritance of early-onset glaucoma: CYP1B1, a potential modifier gene. , 2002, American journal of human genetics.

[104]  Seyed Hassan Paylakhi,et al.  Variable expressivity and high penetrance of CYP1B1 mutations associated with primary congenital glaucoma. , 2009, Ophthalmology.

[105]  R. Esilae,et al.  HISTOCHEMISTRY OF RETINAL ESTERASES , 1964, Acta ophthalmologica.

[106]  Yoshihisa Takahashi,et al.  A Novel Compound Heterozygous Mutation in the CYP4V2 Gene in a Japanese Patient with Bietti's Crystalline Corneoretinal Dystrophy , 2011, Case Reports in Ophthalmology.

[107]  V. H. Lee,et al.  Subcellular distribution of esterases in the bovine eye. , 1982, Current eye research.

[108]  J. Rosenberg,et al.  A closed eye contact lens model of corneal inflammation. Part 1: Increased synthesis of cytochrome P450 arachidonic acid metabolites. , 1995, Investigative ophthalmology & visual science.

[109]  K. Giacomini,et al.  Gene expression profiling of transporters in the solute carrier and ATP-binding cassette superfamilies in human eye substructures. , 2013, Molecular pharmaceutics.

[110]  A. Cohen,et al.  Choline acetyltransferase and acetylcholine esterase activities in normal and biologically fractionated mouse retinas. , 1975, Investigative Ophthalmology.

[111]  R. Anderson,et al.  Lipids of ocular tissues. IV. A comparison of the phospholipids from the retina of six mammalian species. , 1970, Experimental Eye Research.

[112]  B. Bejjani,et al.  Immunolocalization of CYP1B1 in normal, human, fetal and adult eyes. , 2006, Experimental eye research.

[113]  J. Lupski,et al.  Expression patterns of cytochrome P4501B1 (Cyp1b1) in FVB/N mouse eyes. , 2002, Experimental eye research.

[114]  S. Fliesler,et al.  Chemistry and metabolism of lipids in the vertebrate retina. , 1983, Progress in lipid research.

[115]  Tao Zhang,et al.  Drug Transporter and Cytochrome P450 mRNA Expression in Human Ocular Barriers: Implications for Ocular Drug Disposition , 2008, Drug Metabolism and Disposition.

[116]  N. Tanimoto,et al.  Rod and cone a-waves in three cases of Bietti crystalline chorioretinal dystrophy. , 2001, American journal of ophthalmology.

[117]  J. B. Hutchins,et al.  Acetylcholinesterase in the human retina , 1987, Brain Research.

[118]  J. B. Hutchins,et al.  Acetylcholine as a neurotransmitter in the vertebrate retina. , 1987, Experimental eye research.

[119]  P. Rama,et al.  Efficacy of valacyclovir vs acyclovir for the prevention of recurrent herpes simplex virus eye disease: a pilot study. , 2007, American journal of ophthalmology.

[120]  A. Child,et al.  Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1. , 1998, American journal of human genetics.

[121]  G. García-García,et al.  Genotype–Phenotype Analysis of Bietti Crystalline Dystrophy in a Family with the CYP4V2 Ile111Thr Mutation , 2013, Cornea.

[122]  P. Mukherjee,et al.  Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[123]  A. Mitra,et al.  Molecular evidence and functional expression of multidrug resistance associated protein (MRP) in rabbit corneal epithelial cells. , 2006, Experimental eye research.

[124]  M. El Mzibri,et al.  Screening of CYP1B1 and MYOC in Moroccan families with primary congenital glaucoma: Three novel mutations in CYP1B1 , 2010, Molecular vision.

[125]  D. Lewis,et al.  Cytochromes P450 in the bioactivation of chemicals. , 2004, Current topics in medicinal chemistry.

[126]  A. Domb,et al.  Transcorneal and transscleral iontophoresis of dexamethasone phosphate using drug loaded hydrogel. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[127]  T. Lai,et al.  Alterations in serum fatty acid concentrations and desaturase activities in Bietti crystalline dystrophy unaffected by CYP4V2 genotypes. , 2010, Investigative ophthalmology & visual science.

[128]  F. Guengerich,et al.  Characterization of Orphan Human Cytochromes P450 , 2007, Drug metabolism reviews.

[129]  Jin-Ye Wang,et al.  Effect of dietary DHA on DHA levels in retinal rod outer segments in young versus mature rats. , 2003, International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition.

[130]  M. Freeman,et al.  New lives for old: evolution of pseudoenzyme function illustrated by iRhoms , 2012, Nature Reviews Molecular Cell Biology.

[131]  R. Evers,et al.  Interindividual Variability in Hepatic Organic Anion-Transporting Polypeptides and P-Glycoprotein (ABCB1) Protein Expression: Quantification by Liquid Chromatography Tandem Mass Spectroscopy and Influence of Genotype, Age, and Sex , 2014, Drug Metabolism and Disposition.

[132]  Makoto Nakamura,et al.  Bietti crystalline corneoretinal dystrophy associated with CYP4V2 gene mutations. , 2006, Advances in experimental medicine and biology.

[133]  A. Mitra,et al.  Mechanism of Corneal Permeation of L-Valyl Ester of Acyclovir: Targeting the Oligopeptide Transporter on the Rabbit Cornea , 2002, Pharmaceutical Research.

[134]  R. Welch,et al.  Bietti's crystalline dystrophy. A clinicopathologic correlative study. , 1989, Archives of ophthalmology.

[135]  E. Chouery,et al.  Clinical and molecular findings in three Lebanese families with Bietti crystalline dystrophy: Report on a novel mutation , 2012, Molecular vision.

[136]  H. Edelhauser,et al.  The developing corneal endothelium: correlation of morphology, hydration and Na/K ATPase pump site density. , 1991, Current eye research.

[137]  A. Loewenstein,et al.  Drug delivery to the posterior segment of the eye. , 2010, Developments in ophthalmology.

[138]  M. Verma,et al.  CYP1B1 Detection , 2012, Current protocols in toxicology.

[139]  S. Cnattingius,et al.  Association of cytochrome P450 1B1 polymorphism with first-trimester miscarriage. , 2006, Fertility and sterility.

[140]  R. Harrison,et al.  Bietti's tapetoretinal degeneration with marginal corneal dystrophy (crystalline retinopathy): case report. , 1987, The British journal of ophthalmology.

[141]  Y. Li,et al.  Novel mutations in the CYP4V2 gene associated with Bietti crystalline corneoretinal dystrophy. , 2005, Molecular vision.

[142]  Xiaoming Chen,et al.  Overview of Cytochrome P450 1B1 gene mutations in patients with primary congenital glaucoma. , 2011, Experimental eye research.

[143]  N. Bazan,et al.  Membrane docosahexaenoate is supplied to the developing brain and retina by the liver. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[144]  M. Schwartzman,et al.  Corneal epithelial VEGF and cytochrome P450 4B1 expression in a rabbit model of closed eye contact lens wear , 2001, Current eye research.

[145]  Richard S. Smith,et al.  Modification of Ocular Defects in Mouse Developmental Glaucoma Models by Tyrosinase , 2003, Science.

[146]  A. Hofman,et al.  Is open-angle glaucoma associated with early menopause? The Rotterdam Study. , 2001, American journal of epidemiology.

[147]  N. Miyata,et al.  HET0016, a potent and selective inhibitor of 20‐HETE synthesizing enzyme , 2001, British journal of pharmacology.

[148]  S. Pasquaré,et al.  Lipid metabolism in vertebrate retinal rod outer segments. , 2000, Progress in lipid research.

[149]  A. Rettie,et al.  The CYP4 family , 2008 .

[150]  J. Schenkman,et al.  Characterization of the biochemical and structural phenotypes of four CYP1B1 mutations observed in individuals with primary congenital glaucoma , 2008, Pharmacogenetics and genomics.

[151]  A. Rettie,et al.  CYP4B1: An Enigmatic P450 at the Interface between Xenobiotic and Endobiotic Metabolism , 2006, Drug metabolism reviews.

[152]  R. Kim,et al.  Genotyping and site-directed mutagenesis of a cytochrome P450 meander Pro-X-Arg motif critical to CYP4B1 catalysis. , 2003, Toxicology and applied pharmacology.

[153]  S. Feman,et al.  A biochemical characterization of the carboxyl esterases in human subretinal fluid--a study comparing the enzymes in serum, in leukocytes, and in subretinal fluid. , 1977, Experimental eye research.

[154]  P. Treuting,et al.  Inhibition of Retinoic Acid Biosynthesis by the Bisdichloroacetyldiamine WIN 18,446 Markedly Suppresses Spermatogenesis and Alters Retinoid Metabolism in Mice* , 2014, The Journal of Biological Chemistry.

[155]  T. Comery,et al.  Phosphodiesterase 10A Inhibitor Activity in Preclinical Models of the Positive, Cognitive, and Negative Symptoms of Schizophrenia , 2009, Journal of Pharmacology and Experimental Therapeutics.

[156]  G. Amidon,et al.  Identification of a Human Valacyclovirase , 2003, Journal of Biological Chemistry.

[157]  A. Rettie,et al.  Positional specificity of rabbit CYP4B1 for omega-hydroxylation1 of short-medium chain fatty acids and hydrocarbons. , 1998, Biochemical and biophysical research communications.

[158]  S. Kingman.  Glaucoma is second leading cause of blindness globally. , 2004, Bulletin of the World Health Organization.

[159]  P. Majumder,et al.  A polymorphism in the CYP1B1 promoter is functionally associated with primary congenital glaucoma. , 2010, Human molecular genetics.

[160]  M. Ingelman-Sundberg,et al.  Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles. , 2005, Toxicology in vitro : an international journal published in association with BIBRA.

[161]  Eric F. Johnson,et al.  Structural Characterization of the Complex between α-Naphthoflavone and Human Cytochrome P450 1B1* , 2010, The Journal of Biological Chemistry.